Abstract:Most of the therapeutic antibodies approved for clinical use are full-size IgG1 molecules. The interaction of the IgG1 Fc with the neonatal Fc receptor (FcRn) plays a critical role in maintaining their long half-life. We have hypothesized that isolated Fc domains could be engineered to functionally mimic full-size IgG1 (nanoantibodies) but with decreased (10-fold) size. Here, we report for the first time the successful generation of a soluble, monomeric CH3 domain (mCH3). In contrast to the wild-type dimeric CH3, the mCH3 exhibited pH-dependent binding to FcRn similar to that of Fc. The binding free energy of mCH3 to FcRn was higher than that of isolated CH2 but lower than that of Fc. Therefore, CH3 may contribute a larger portion of the free energy of binding to FcRn than CH2. A fusion protein of mCH3 with an engineered antibody domain (m36.4) also bound to FcRn in a pH-dependent fashion and exhibited significantly higher neutralizing activity against HIV-1 than m36.4-Fc fusion proteins. The m36.4-mCH3 fusion protein was monomeric, stable, soluble, and expressed at a high level in Escherichia coli. We also found that engineering an additional disulfide bond in mCH3 remarkably increased its thermal stability, whereas the FcRn binding was not affected. These data suggest that mCH3 could not only help in the exploration of the dual mechanisms of the CH3 contribution to Fc functions (dimerization and FcRn interactions) but could also be used for the development of candidate therapeutics with optimized half-life, enhanced tissue penetration, access to sterically restricted binding sites, and increased therapeutic efficacy.Background: The CH3 domain of an antibody is a homodimer.Results: Soluble monomeric IgG1 CH3 (mCH3) exhibits pH-dependent binding to FcRn.Conclusion: The mCH3 can be used as a new scaffold for generation of binders with potentially enhanced half-life.Significance: The mCH3 is a promising fusion partner for therapeutic proteins with increased therapeutic efficacy. Most of the therapeutic antibodies approved for clinical use are full-size IgG1 molecules. The interaction of the IgG1 Fc with the neonatal Fc receptor (FcRn) plays a critical role in maintaining their long half-life. We have hypothesized that isolated Fc domains could be engineered to functionally mimic full-size IgG1 (nanoantibodies) but with decreased (10-fold) size. Here, we report for the first time the successful generation of a soluble, monomeric CH3 domain (mCH3). In contrast to the wild-type dimeric CH3, the mCH3 exhibited pH-dependent binding to FcRn similar to that of Fc. The binding free energy of mCH3 to FcRn was higher than that of isolated CH2 but lower than that of Fc. Therefore, CH3 may contribute a larger portion of the free energy of binding to FcRn than CH2. A fusion protein of mCH3 with an engineered antibody domain (m36.4) also bound to FcRn in a pH-dependent fashion and exhibited significantly higher neutralizing activity against HIV-1 than m36.4-Fc fusion proteins. The m36.4-mCH3 fusion protein was monomeric, stable, soluble, and expressed at a high level in Escherichia coli. We also found that engineering an additional disulfide bond in mCH3 remarkably increased its thermal stability, whereas the FcRn binding was not affected. These data suggest that mCH3 could not only help in the exploration of the dual mechanisms of the CH3 contribution to Fc functions (dimerization and FcRn interactions) but could also be used for the development of candidate therapeutics with optimized half-life, enhanced tissue penetration, access to sterically restricted binding sites, and increased therapeutic efficacy. Background: The CH3 domain of an antibody is a homodimer. Results: Soluble monomeric IgG1 CH3 (mCH3) exhibits pH-dependent binding to FcRn. Conclusion: The mCH3 can be used as a new scaffold for generation of binders with potentially enhanced half-life. Significance: The mCH3 is a promising fusion partner for therapeutic proteins with increased therapeutic efficacy.

Chimerism of avian IgY‐scFv and truncated IgG‐Fc: A novel strategy in cross‐species antibody generation and enhancement

Abstract 2584: Development of an Fc gamma receptor fully-humanized mouse model to support the accurate preclinical study of therapeutic antibodies

Construction and Expression of a Human/mouse Chimeric CD19 Monoclonal Antibody: Successful Modification of a Murine IgM to a Chimeric IgG.

Successful construction and massive expression of a novel Anti-CD19 human-mouse chimeric antibody Hm2E8b.

Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics.

Engineered Soluble Monomeric IgG1 Fc with Significantly Decreased Non-Specific Binding

Design of a Novel Fab-Like Antibody Fragment with Enhanced Stability and Affinity for Clinical use

Construction and Expression of Single-Chain Antibody Derived from a New Clone of Monoclonal Antibody Against Human CD14 in CHO Cells

Heavy chain-only antibodies with a stabilized human VH in transgenic chickens for therapeutic antibody discovery

A general Fc engineering platform for the next generation of antibody therapeutics

Fc engineering by monoclonal mammalian cell display for improved affinity and selectivity towards FcγRs

Engineered Fc Based Antibody Domains and Fragments As Novel Scaffolds.

Antibody Fc-chimerism and effector functions: When IgG takes advantage of IgA

Soluble Monomeric IgG1 Fc

Convenient method of producing cyclic single-chain Fv antibodies by split-intein-mediated protein ligation and chaperone co-expression

Engineering Bifunctional Antibodies With Constant Region Fusion Architectures

Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life

Functional humanization of immunoglobulin heavy constant gamma 1 Fc domain human FCGRT transgenic mice

Generation of a Phage Display Chicken Single-Chain Variable Fragment Library

Generation of Chicken Antibody Libraries and Selection of Antigen Binders

Engineered Soluble Monomeric IgG1 CH3 Domain